10-Q quarterly report · filed Nov 13, 2026

OptimizeRx Corp (OPRX) Q3 2026 10-Q Quarterly Report

Short answer

OptimizeRx Corp (OPRX) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $22M (down 17.1% year over year) with net income of $1M.

Q3 2026 key financials · XBRL

Revenue
$22M
−17.1% YoY · +5.4% QoQ
Net income
$1M
+53.4% YoY · +270.0% QoQ
Operating margin
12.4%
EPS (diluted)
$0.06
+20.0% YoY · +300.0% QoQ

Source: XBRL data from the OptimizeRx Corp (OPRX) Q3 2026 10-Q on SEC EDGAR. USD.

OptimizeRx Corp Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $21,615, down 17% YoY from $26,067, reflecting managed-service declines and measured customer spending
  • Operating margin 12.4% vs 7.9% YoY, with net income $1,195 vs $779
  • Cost of revenue margin 25% vs 33%, driven by exiting low-margin managed services
  • Operating cash flow $12,880 vs $11,627; cash $22,325 and undrawn revolver $10,000
  • Outlook: sufficient liquidity for 12 months, with headwinds from tariffs, macroeconomic uncertainty and customer budget scrutiny

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Carried-forward business risks could materially affect operations and financial condition
  • Additional unidentified or currently immaterial risks could adversely affect operating results

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other OptimizeRx Corp quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.